First Patient in Biosergen Clinical Trial Treating with BSG005 for Life Threatening Fungal Infection
Stockholm, Sweden – July 12, 2024 – Biosergen AB (“Biosergen”) is pleased to announce that the first patient suffering from an invasive fungal infection has been dosed with BSG005 as rescue therapy.‘Today marks a significant milestone as the first patient has received the first dose of our lead candidate BSG005. The goal with the study is to increase survival rates for these very ill patients with difficult to treat fungal strains or/and with resistance to current antifungal treatment. There is a significant unmet medical need for the many millions of people infected with and dying from